Compound Advantage

The DuraSite^® technology platform can be customized to deliver a wide variety of potential drug candidates. This powerful drug delivery technology offers a number of benefits for potential ocular drug candidates:

• Improved residence time in the tear film
• Improved absorption by the conjunctiva and cornea
• Dramatically reduced dosing schedule with potential once-a-day dosing
• Improved patient compliance
• Known safety profile
• Compatible with small molecules to high molecular weight proteins

For information about DuraSite technology licensing and partnership opportunities, contact Lyle Bowman at lylebo@insite.com.